Europe
Oxford Gene Technology, A Sysmex Group Company, has developed a breakthrough targeted NGS panel for constitutional cytogenetics research.
BioArctic AB will be strengthening its management team in 2020 through two strategic recruitments.
Creoptix AG announced the appointment of Line Stigen Raquet as Chief Executive Officer with effect from beginning of January 2020.
Promore Pharma AB announce that all patients in the company’s Phase IIb-study with LL-37 for treatment of venous leg ulcers have been recruited.
Data on 52 patients in the 145-patient clinical trial highlight ADCT-402 (loncastuximab tesirine) continues to demonstrate anti-tumor activity and manageable toxicity in heavily pretreated patients
Research shows modulation of the Hedgehog and androgen signaling pathways to discontinue the vicious circle leading to inflammation in the central nervous system and chronic demyelination
PHARMASEAL, a new provider of clinical trial management and governance solutions to enter the market, announces that is has won Start-Up of the Year in the 2019 Medilink East Midlands Business Awards.
The Dutch company Xenikos B.V., which develops innovative immunotherapies for treating patients with severe immune disease and post-transplant rejection, reports data from an expanded access program using T-Guard to treat steroid-refractory acute graft-versus-host disease in patients following allogeneic stem cell transplantation.
The National Eye Hospital of the Quinze- Vingts in Paris and GenSight Biologics announced that the French Competent Authority, the National Drug Safety Agency, granted a named patient Temporary Authorization for Use for LUMEVOQTM to the CHNO of the Quinze-Vingts.
Despite having one of the best-selling insulin products on the market, Sanofi is exiting diabetes and cardiovascular research and development in favor of more lucrative areas, particularly cancer research.
PRESS RELEASES